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Abstract
Alveolar echinococcosis (AE) in humans is a parasitic disease characterized by severe damage to the liver and occasionally
other organs. AE is caused by infection with the metacestode (larval) stage of the fox tapeworm Echinococcus multilocularis,
usually infecting small rodents as natural intermediate hosts. Conventionally, human AE is chemotherapeutically treated
with mebendazole or albendazole. There is, however still the need for improved chemotherapeutical options. Primary in
vivo studies on drugs of interest are commonly performed in small laboratory animals such as mice and Mongolian jirds, and
in most cases, a secondary infection model is used, whereby E. multilocularis metacestodes are directly injected into the
peritoneal cavity or into the liver. Disadvantages of this methodological approach include risk of injury to organs during the
inoculation and, most notably, a limitation in the macroscopic (visible) assessment of treatment efficacy. Thus, in order to
monitor the efficacy of chemotherapeutical treatment, animals have to be euthanized and the parasite tissue dissected. In
the present study, mice were infected with E. multilocularis metacestodes through the subcutaneous route and were then
subjected to chemotherapy employing albendazole. Serological responses to infection were comparatively assessed in mice
infected by the conventional intraperitoneal route. We demonstrate that the subcutaneous infection model for secondary
AE facilitates the assessment of the progress of infection and drug treatment in the live animal.
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Introduction
Echinococcus multilocularis, known as the fox tapeworm, is a
parasite of the Taeniidae family, whose metacestode (larval) stage
causes the zoonotic disease ‘‘alveolar echinococcosis (AE)’’ in the
intermediate hosts including humans. [1]. The disease displays a
clinical manifestation similar to that of a slow-growing malignant
tumor of the liver. The continuously proliferating parasite
progressively invades the liver parenchyma, bile ducts and blood
vessels, which results in symptoms related to biliary obstruction,
portal hypertension and others. Secondary infection upon
dissemination of metacestode structures via the blood or lymphatic
system is most commonly found in adjacent organs such as the
lungs, but also in the brain [2] and other more remote sites.
The treatment options for AE are surgery and/or chemother-
apy. The feasibility of surgery depends on the number, location
and extension/size of the metacestode lesion. In addition, care
must be taken to remove the entire parasite mass, otherwise
recurrences might occur, and there is the risk of metastasis
formation by accidental dissemination of small daughter vesicles,
cells or cell-conglomerates. Surgery (radical or palliative) is always
accompanied by pre- and post-operative chemotherapy. In cases
where surgery is not possible, chemotherapy remains the only
option. For chemotherapeutical treatment of AE, the only two
drugs licensed to date are the benzimidazole carbamate derivatives
albendazole and mebendazole. Both exhibit a relatively good
clinical efficacy but side effects may occur, and for most cases the
drugs do not act parasitocidal [3,4].
In order to identify better drugs for the treatment of AE, several
compounds have been investigated in the past, either employing in
vitro cultured parasites and/or in vivo rodent models [3,5]. The
secondary murine AE model is currently used for experimental
treatment trials [6]. In this model, the parasite metacestodes are
injected into the peritoneal cavity of a mouse or a Mongolian jird
(Meriones unguiculatus), where the parasites proliferate and develop
tumour-like features such as progressive growth and invasion of
neighbouring tissues. Considerable organ damage might be
inflicted by injection, and parasite growth can only be assessed
by the dissection of the animals at the end of the study.
In the frame of the present study, we propose that subcutaneous
injection of the parasite represents a viable alternative. This
route represents, in comparison to the intraperitoneal route, a
reduced risk of organ damage and of secondary infection.
Subcutaneous models have been used in animal models for cancer
studies since 1946, and offer the advantage that tumors are
readily visible from the outside, thus facilitating the direct visual
monitoring of cancer progression upon treatment [7]. Subcutane-
ously injected metacestodes have been recently employed to
prove the efficacy of radiotherapy [8]. The aim of the present
study was to verify whether the subcutaneous infection model for
AE was also applicable to monitor and assess the effects of
chemotherapy.
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Materials and Methods
Media and biochemicals
If not stated otherwise, all culture media and reagents were
purchased from Gibco-BRL (Zu¨rich, Switzerland) and biochem-
ical reagents were from Sigma (St. Louis, Mo, USA). Albendazole
was purchased from Sigma (St. Louis, Mo, USA).
In vitro culture of E. multilocularis metacestodes
Culture of E. multilocularis (isolate H95) was carried out as
previously described [9,10]. In short, metacestodes dissected
from experimentally infected Balb/c mice were pressed through
an autoclaved metal tea strainer. The metacestodes were
incubated in antibiotic solutions: 20 mg/mL Levoflaxin (Aventis,
Meyrin, Switzerland) and 20 mg/mL Ciprofloxacin (Bayer,
Zu¨rich, Switzerland), in PBS overnight. The sedimented material
was washed several times with 16PBS and 1 mL was added to a
cell-culture flask containing 56106 rat hepatoma (ATCC: CRL-
1600) cells/50 mL cultivation-medium (DMEM, 10% FCS,
100 U/mL Penicillin G, 100 mg/mL Streptomycin sulphate).
These co-cultures were incubated at 37uC, 5% CO2, with medium
changes once a week. Splitting of cultures was carried out when
exceeding 15 mL total metacestode volume. Metacestodes were
used for experimental procedures when they reached diameters of
,4 mm.
Comparative studies on the efficacy of albendazole
treatment in Balb/c mice experimentally infected
through the subcutaneous or intraperitoneal route
Twenty-four female Balb/c mice (age 9 weeks; body weight 20–
25 g) were housed in a temperature-controlled light cycle room
with food and water ad libitum. Experiments were carried out
according to the Swiss Animal Welfare regulations, and experi-
ments were approved by the Board for Supervison of Animal
Research of the Canton of Bern (license No. BE103/11). 10 mice
were infected by intraperitoneal (ip) injection of metacestodes, and
another 10 mice were infected subcutaneously (sc), each with
100 ml of homogenized in vitro cultivated metacestode material
(isolate H95). 4 control animals remained uninfected. After 6
weeks, the infected animals were allocated into 4 experimental
groups with 5 mice each: (i) sc infection and albendazole treatment
(scABZ); (ii) sc infection and mock treatment (sc-untreated); (iii) ip
infection and albendazole treatment (ipABZ); (iv) ip infection and
mock treatment (ip-untreated). Additionally, 2 of the uninfected
animals were treated with albendazole and 2 were mock-treated
(controls). Drug treatments were carried out by daily oral
application of albendazole (200 mg/kg) suspended in 100 ml of a
1:1 mixture of honey (M-Budget honey, Migros Switzerland) and
1% CMC (carboxymethyl cellulose sodium salt) as described
earlier [11]. Mock treatments were performed by oral application
of 100 ml honey/CMC. The animals were photographed and
weighted periodically throughout the treatment.
At the end of the study the animals were euthanized, necroscopy
was performed, the entire parasite tissue was recovered and the
parasite weight was determined. Several samples of the recovered
material were processed for TEM. Parasite weights were analyzed
by boxplots, and outliers were identified by the ESD method
(extreme studentized deviate) with a significance level of 0.05 (two-
sided). Only one outlier was identified and discarded in the
subcutaneously infected and treated group, which showed P.0.05
in relation to the other values within the group. The remaining
data were submitted to a two-tailed distributed student t-test, with
two-sample equal variance between the untreated groups and the
treatment groups. The uninfected control animals were not
included in the calculations.
Serology
Blood was taken at the time of euthanasia by heart puncture
and serum was obtained after centrifugation. The humoral
immune response was assessed by ELISA, detecting specific
antibodies against E. multilocularis antigens such as Em18 [12],
Em2 [13] and vesicular fluid [14]. Vesicular fluid was obtained
from in vitro cultured E. multilocularis metacestodes by gently
breaking them with a pipette, and subsequent centrifugation at
6006g for 5 min at RT to separate vesicle fluid from vesicle walls.
The supernatant (containing vesicle fluid) was collected, sterile
filtered (0.2 mm), and stored at -80uC. Em2(G11)-antigen was
obtained by affinity chromatography as previously described
[15]. Recombinant Em18 was expressed and purified as described
[16].
For ELISA, 96 well plates were coated overnight at 4uC with
vesicular fluid (1 mg protein/mL), or Em2(G11)-antigen (2.8 mg
carbohydrate/mL in a dilution of 1:200) and recombinant Em18
(0.4 mg protein/mL) antigens diluted in coating buffer (0.05 M
NaHCO3–Na2CO3, pH 9.6). The plates were then washed 36
with washing buffer (1.5 mM KH2PO4, 10 mM Na2HPO4,
150 mM NaCl, 2.5 mM KCl, pH 7.4), blocked for 30 min at
37uC with 100 ml per well of dilution buffer (washing buffer
supplemented with 1% horse serum). Serum samples were diluted
1:100 in dilution buffer and incubated in microplates for 60 min at
37uC. After extensive washing, the plates were incubated for
30 min at 37uC with goat anti-mouse IgG alkaline phosphatase
(AP) conjugate (Promega, Madison, WI, USA) at a dilution of
1:1000. Following three washes, the wells were incubated with
100 ml of AP substrate (1 mg/mL p-nitrophenyl–phosphate–
disodium in 1 M di-ethanolamine containing 0.1 mM MgCl2,
pH 9.8) for 30 minutes, and then the reaction was stopped by the
addition of 30 ml 3 M NaOH. The absorbance at 405 nm was
measured at room temperature in a tunable microplate reader
(Dynatech, Embrach, Switzerland). Conjugate controls, blanks
and mouse positive and negative controls were performed in
parallel. For each sample duplicate measures were performed. The
data was submitted to a 2-tailed, homoscedastic Student t test, with
2-sample equal variance.
Author Summary
Alveolar echinococcosis is a disease which affects humans
and inflicts severe damage to the liver and other organs. It
is caused by a parasite whose definitive host is the fox.
Despite being a relatively rare disease, an increasing
number of new cases has been reported in central and
eastern European countries more recently. The current
therapy in human AE patients consists of benzimidazoles.
The treatment has to be taken on a daily basis for very
long periods of time, or even lifelong. New options are
currently being searched for, mainly based on compounds
that show efficacy in experimental animal infection
models. The infection is commonly done by injecting
parasites directly into the peritoneal cavity of the animals,
with risk of damage to the surrounding organs. The
efficacy of applied treatments can only be evaluated at the
end of the studies by dissection of the animals. In this
study we show that the subcutaneous infection model can
be applied for drug treatment trials and enables the direct
monitoring of treatment effects during the entire study
period.
Subcutaneous Alveolar Echinococcosis in Mice
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Transmission electron microscopy (TEM)
To visualize the structural alterations in metacestodes imposed
by the albendazole treatment in both models, the parasites
harvested at the time point of euthanasia were processed for
transmission electronic microscopy (TEM). Briefly, metacestodes
were fixed in 2.5% glutaraldehyde in 100 mM sodium cacodylate
buffer (pH 7.2) for 2 h at room temperature, followed by
postfixation in 2% OsO4 in 100 mM sodium cacodylate buffer
(pH 7.2) for 2 h at room temperature. The fixed specimens were
washed in distilled water, and were treated with 1% uranyl acetate
for 30 min, dehydrated through a graded series of ethanol (30-50-
70-90-36100%) and were finally embedded in epoxy resin (Epon
812) with three changes of resin during two days. Resin
polymerization was carried out at 65uC overnight. Sections of
80–90 nm thickness were cut on a Reichert and Jung ultra-
microtome, loaded onto 300-mesh copper grids (Plano GmbH,
Marburg, Germany), and stained with uranyl acetate and lead
citrate as previously described [17]. Specimens were viewed on a
Phillips EM400 transmission electron microscope operating at
80 kV.
Results and Discussion
Parasite burden of intraperitoneal (ip) and subcutaneous
(sc) infection models
The parasite weights recovered from ip and sc infected Balb/c
mice, treated or not with albendazole, are depicted in Fig. 1A.
The sc-untreated group yielded 63% less parasite material
compared to the ip-untreated group. This difference in the
progress of parasite development might be due to the more
restricted physical space for growth provided in the sc infection
model, or due to difference in the immune responses triggered by
the presence of the parasites at the two different sites. This could
also be observed throughout the treatment, reflected in the weights
of the individual mice of different groups (Fig. 1B). As the weight
of the animals can be correlated to parasite growth, the weight
progression of the animals can also be used as a parameter for
monitoring the effects of chemotherapy. This is confirmed by the
steady weight increase of the untreated groups throughout the
experiment, while the average weight of both treated groups
reached a plateau around 70 days post-infection, or 30 days after
the beginning of treatment, due to the effects of chemotherapy on
parasite growth. Thus, the weight of the mice could be correlated
to the growth of the parasite (Fig. 1B).
Daily oral application of albendazole yielded the expected
results, namely a significantly decreased parasite weight [6,18,19].
The ipABZ and scABZ groups were compared to their respective
ip-untreated and sc-untreated control groups. A decrease in the
amount of harvested parasite material of 73% was observed in the
sc infected mice (P=5.8461025), while for the ip infected mice
(P=4.4361024) a decrease of 62% was observed.
Besides the decreased risk of injury presented by the sc injection
of metacestodes, the sc model also enables an easy monitoring of
infection and treatment. This is shown in Figure 2. In the sc
infected mice, the initial growth and subsequent inhibition of
parasite growth upon treatment are both visible by eye (Figure 2B),
but this does not hold true for the ip infected mice, where a visible
reduction in parasite mass would only be evident upon even more
prolonged treatment (unpublished observations). These results are
consistent with the animal’s progression of weight, as mentioned
above. Thus, the sc infection model offers the additional
advantage of enabling the researcher to detect potential treatment
efficacy within a shorter time span compared to the ip infection
model. Moreover, for experiments covering a longer time span, no
mobility impairment was observed in the sc infected mice, in
contrast to ip infected animals, where increased parasite mass can
lead to impaired mobility. This is due to the location of the
infection (ventral opposed to dorsal) and the virtually unrestricted
parasite growth in the peritoneal cavity of infected animals.
Although no extensive studies were performed on potential
metastasis of the parasite for both infection models, invasion of
adjacent tissues was not observed in sc infected mice. This renders
the sc infection model unsuitable for studies on metastasis
formation. On the other hand, the sc infection model would
permit injection of different E. multilocularis isolates into the same
mouse at multiple sites.
Structural damage of the parasite caused by drug
treatment
TEM was employed to visualize and compare the effects of
albendazole treatment on ip and sc infected mice as shown in
Figure 3.
Untreated E. multilocularis metacestodes exhibited the typical
features described previously [20]. The most outer acellular and
carbohydrate-rich laminated layer surrounding the entire parasite
is clearly visible and in close contact with the host tissue. (Fig. 3 A–
D). The live parasite tissue is localized just adjacent to the inner
surface of the laminated layer, with the tegument forming
microtriches that protrude into the laminated layer. The germinal
layer is constituted by a relatively densely packed tissue containing
muscle cells, connective tissue, undifferentiated cells, and mostly
Figure 1. Parasite burden and weight control. A) Parasite burden
of intraperitoneally (ip) and subcutaneously (sc) infected animal models.
Albendazole treatment was initiated at 6 weeks post-infection. Each
treatment group comprised 5 infected animals. scABZ and ipABZ
groups received albendazole in honey/CMC, sc-untreated and ip-
untreated groups received honey/CMC without compound. The P
values indicate the scores obtained by student’s t-test in comparison
with the respective untreated groups. B) Weight control of mice
throughout the study. Representation of average weight of different
experimental groups at defined timepoints during the study. Treat-
ments were initiated at day 42 p.i. The non-infected controls are not
shown. The groups were divided into route of infection (subcuta-
neous = sc; intraperitoneal = ip), and in albendazole-treated (scABZ;
ipABZ) or non-treated (sc-untreated; ip-untreated).
doi:10.1371/journal.pntd.0002235.g001
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fully-loaded glycogen storage cells. TEM micrographs taken of the
scABZ group show severe drug-induced alterations in the
structural integrity of the germinal layer and a complete loss of
microtriches (Fig. 3 E–G). These alterations are similar to those
described earlier in metacestodes obtained from ip infected Balb/c
mice [6]. In addition, the laminated layer seems to be reduced in
width upon treatment, probably due to the fact that the parasite
tissue forming the laminated layer has been severely metabolically
impaired during treatment and synthesis as well as secretion of
laminated layer components was halted (Fig. 3). Similar damage
was observed in the ipABZ group (results not shown).
Serological comparison of sc and ip infected mice
In order to characterize the humoral immune responses of the
mice in the different infection models, blood samples were taken at
the time point of euthanasia and serum was obtained. ELISA
detected antibodies against Em18 [12], Em2 [13] and vesicle fluid
[14]. The results in Figure 4 show that the ip-untreated or sc-
untreated groups exhibit a largely identical antibody reactivity
pattern, even though the antibody levels are slightly lower in sc
infected mice. They showed no significant difference in the
humoral immune response of both groups (P=0.08 for Em18;
P=0.04 for Em2 and P=0.85 for vesicle fluid). The same was
Figure 2. Visible monitoring of mice during treatment. The animals were photographed at week 1, and week 8 of treatment. The arrows
indicate the site of subcutaneous infection. Subcutaneously infected animals are shown in panels A (untreated), and B (treated with albendazole).
One example of each group is shown. Note that the parasite burden in B does not increase upon treatment. This is not visible in intraperitoneally
infected mice, but detectable in the subcutaneous model despite the considerably impaired parasite growth due to albendazole treatment (not
shown).
doi:10.1371/journal.pntd.0002235.g002
Figure 3. TEM of metacestodes recovered from untreated and subcutaneously infected treated mice. Metacestodes recovered from
intraperitoneally (A and B) and subcutaneously (C and D) infected mice exhibit a well-defined laminated layer (LL), which is in close physical contact
with adjacent host tissue (ht). The tegument, with microtriches (arrows) protruding well into the LL, and the germinal layer (GL) exhibiting
undifferentiated cells and glycogen storage cells, are clearly visible. Metacestodes from animals subcutaneously infected and treated orally with
albendazole show a reduced and less defined laminated layer (LL), which maintains contact with host tissue components. This is clearly visible in G.
Other alterations can be seen in E and F, such as the loss of integrity of the germinal layer (GL) and the absence of microtriches (for comparison refer
to A–D). Similar structural damage was observed on the material collected from intraperitoneally infected animals treated with albendazole (results
not shown).
doi:10.1371/journal.pntd.0002235.g003
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observed for the scABZ and ipABZ treated groups (P=0.23 for
Em18; P=0.23 for Em2 and P=0.74 for vesicle fluid). Thus, in
both infection models treatments with albendazole did not seem to
affect the specific antibody synthesis.
Conclusion
Using treatment with albendazole, we have shown that the sc
infection model is suitable for investigating the effects of
chemotherapeutically interesting compounds against secondary
murine AE. This model has the advantage over the conventional
ip model of facilitating visual monitoring throughout the course of
treatment. It remains to be investigated whether it can be used to
assess the effect of other drugs apart from albendazole, thus
representing a general model for research concerning chemother-
apy.
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